[Tumor-induced hypercalcemia. Review of bisphosphonate treatment].
The incidence of tumor-induced hypercalcemia is between 10 to 20%. New treatments justify this review article. Tumor-induced hypercalcemia (half of all hypercalcemia) is divided into two groups: hematological tumors (10%), and solid tumors (90%), with osteolytic hypercalcemia and humoral hypercalcemia of malignancy (HHM: mediators include PTHrP). The two most common causes of tumor-induced hypercalcemia are lung cancer and breast cancer. Tumor-induced hypercalcemia most commonly disturbs gastrointestinal, neurological, renal and cardiovascular functions. These symptoms may be erroneously attributed to the underlying malignancy or its therapy. Prognosis of tumor-induced hypercalcemia is very poor, with median survival being about 3 months. Bisphosphonates have emerged as the standard treatment of tumor-induced hypercalcemia. The intravenous administration of isotonic saline is the first step in the management of tumor-induced hypercalcemia. Specific treatment of cancer remains essential to prevent TIH relapse. New bisphosphonates have appeared, the most potent known bisphosphonate today is zoledronate.